Analyst Ratings For Conatus Pharmaceuticals (NASDAQ:CNAT)
Today, HC Wainwright reiterated its Buy rating on Conatus Pharmaceuticals (NASDAQ:CNAT) with a price target of $17.00.
Some recent analyst ratings include
- 3/8/2018-HC Wainwright Reiterated Rating of Buy.
- 2/8/2018-Roth Capital initiated coverage with a Buy rating.
- 10/6/2017-Seaport Global Securities Reiterated Rating of Buy.
- 8/3/2017-Stifel Nicolaus Reiterated Rating of Buy.
- 5/15/2017-Aegis Reiterated Rating of Buy.
Recent Insider Trading Activity For Conatus Pharmaceuticals (NASDAQ:CNAT)
Conatus Pharmaceuticals (NASDAQ:CNAT) has insider ownership of 13.90% and institutional ownership of 39.57%.
- On 4/8/2015 Daniel L Kisner, Director, bought 4,000 with an average share price of $5.75 per share and the total transaction amounting to $23,000.00.
- On 7/30/2013 David F Hale, Director, bought 2,588 with an average share price of $11.00 per share and the total transaction amounting to $28,468.00.
- On 7/30/2013 Luke Evnin, Major Shareholder, bought 165,265 with an average share price of $11.00 per share and the total transaction amounting to $1,817,915.00.
- On 7/30/2013 Steven J Mento, CEO, bought 13,800 with an average share price of $11.00 per share and the total transaction amounting to $151,800.00.
Recent Trading Activity for Conatus Pharmaceuticals (NASDAQ:CNAT)
Shares of Conatus Pharmaceuticals closed the previous trading session at 7.07 up +0.19 2.76% with 6.900000095367432 shares trading hands.
